Position in BHVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$13,480,312
+$448,148 QoQ
Shares Held
905,935
-41.2% QoQ
Ownership
0.600%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#34
of 294 holders
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BHVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,042,063 across 169 Biotechnology names. BHVN ranks #38 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in BHVN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,480,312 | 905,935 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $13,032,164 | 1,540,445 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,732,186 | 1,570,610 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $18,996,610 | 1,265,597 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,911,058 | 135,440 | Shares | Sole | 2025-08-14 | |
| 2024-06-30 | $3,050,210 | 87,877 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $93,027 | 1,701 | Shares | Sole | 2024-05-14 | |
| 2023-09-30 | $781,652 | 30,052 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||